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Abstract
Background: A routine method for the quantification of beryllium in biological fluids is essential
for the development of a chelation therapy for Chronic Beryllium Disease (CBD). We describe a
procedure for the direct determination of beryllium in undigested micro quantities of human blood
and serum using graphite furnace atomic absorption spectrometry. Blood and serum samples are
prepared respectively by a simple 8-fold and 5-fold dilution with a Nash Reagent. Three
experimental setups are compared: using no modifier, using magnesium nitrate and using palladium/
citric acid as chemical modifiers.
Results: In serum, both modifiers did not improve the method sensitivity, the optimal pyrolysis
and atomization temperatures are 1000°C and 2900°C, respectively. In blood, 6 μg of magnesium
nitrate was found to improve the method sensitivity. The optimal pyrolysis and atomization
temperatures were 800°C and 2800°C respectively.
Conclusion: In serum, the method detection limit was 2 ng l-1, the characteristic mass was 0.22
(± 0.07) pg and the accuracy ranged from 95 to 100%. In blood, the detection limit was 7 ng l-1, the
characteristic mass was 0.20 (± 0.02) pg and the accuracy ranged from 99 to 101%.
Background
Beryllium is the 35th most abundant element in the earth's
crust, with an average of 6 mg kg-1 [1]. It has unique phys-
ical and chemical properties that improves the character-
istics of alloys producing greater tensile strength, high
electrical and thermal conductivity, along with good cor-
rosion and fatigue resistance [2]. Beryllium and its metal
alloys have been widely used for electrical equipment,
electronic instrumentation, structural components for air-
craft, missiles, satellites and nuclear reactors [3,4].
Beryllium and its compounds are very toxic. They can
cause chronic beryllium disease (CBD), a lung disorder
initiated by an electrostatic interaction with the MHC
class II human leukocyte antigen (HLA) [5]. Recent
molecular epidemiological studies found a significant
correlation between the risk of developing CBD and the
predicted surface electrostatic potential of the HLA-DP
alleles, suggesting that individuals who carry the most
negatively charged alleles are at greater risk of beryllium
sensitization and CBD [6]. Because of these findings,
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increased research efforts are being targeted towards the
development of a CBD treatment by chelation therapy
[7,8]. For that purpose, a routine method is required to
analyse beryllium in micro samples of biological fluids
with high sensitivity, accuracy, and low detection limits.
The commonly used methods for the determination of
beryllium in tissues and urine include fluorometric [9,10],
gas chromatographic [11-14], atomic emission [15-17],
inductively coupled plasma mass spectrometry (ICP-MS)
[18-21] and atomic absorption [22-25]. Fluorometric
methods are sensitive (Be detection limit of 5 ~ 10 μg L-1)
[10] but require extensive sample preparation, derivatiza-
tion and relatively large sample volumes. Gas chromato-
graphic methods have sufficient sensitivity and selectivity
when coupled with mass spectrometry (Be detection limit
of 30 ~ 40 μg L-1) [14], but they require a laborious, multi-
step derivatization. Atomic emission, either arc emission
or inductively coupled plasma emission are sensitive and
accurate (Be detection limit of 0.2 ~ 1 μg L-1) [16], but
often require large sample volumes and multi-steps prep-
aration often including digestion. Inductively coupled
plasma mass spectrometry (ICP-MS) recently became the
methode of choice for biomonitoring trace elements in
biological matrices (blood, plasma, urine, etc). It is a
multi-elementary method that offer outstanding sensitiv-
ity, accuracy and detection limit in the low ng L-1 with a
reported beryllium detection limit in the range of 5 to 20
ng L-1 depending on the matrix [20]. As for the atomic
absorption methods, graphite furnace atomic spectrome-
try (GF-AAS) with a suitable chemical modifier (such as,
lutetium [26], ammonium 12-molybdophosphate [27],
palladium [28] and magnesium nitrate [24]) has been
widely used for the analysis of beryllium in urine, envi-
ronmental samples and tissue digests with detection lim-
its in the range of 2 to 20 ng L-1. Limited work is published
on the determination of beryllium in human serum,
blood or biological fluids. The objective of this study is to
develop a simple procedure for the direct determination
of beryllium in undigested micro quantities of human
blood and serum using GF-AAS as a routine analytical
method. The analyses were performed by simple 5-fold
and 8-fold dilution of the serum and blood respectively
with a Nash reagent (NR) containing nitric acid, ammo-
nium hydroxide, Triton X-100, antifoam B and EDTA
[21,29]. We also compared three different experimental
setups: using no modifier, using magnesium nitrate and
using palladium/citric acid (reduced palladium) as chem-
ical modifiers in order to study their effect on beryllium
quantification in such complex matrices. We selected
magnesium nitrate, known to improve beryllium sensitiv-
ity by a factor of 1.5 to 2 in matrices rich in halide ions
(e.g. urine and environmental samples [24,27]) and
reduced palladium, one of the commonly-used modifiers
in GF-AAS analysis known to stabilize the atomization
process regardless of the matrix complexity were evaluated
[30-32]. Optimal pyrolysis and atomization conditions,
detection limits and characteristic mass (the mass of ele-
ment generating 0.0044 absorbance) were determined in
order to develop a rapid and precise method for beryllium
analysis in human blood and serum. The accuracy of the
analytical method is tested with a control sample
(Seronorm trace elements whole blood (STEWB) Level 2).
Results and discussion
Optimization of the furnace temperature program
Beryllium has a high boiling temperature of 2479°C. In
general, it should not be lost during the pyrolysis stage
unless it is complexed with organic compounds or halide
ions. In all experimental set-ups, a pre-pyrolysis stage at
450°C was introduced in the temperature program to
generate a slow pyrolysis of the blood and serum matrices.
This pre-pyrolysis step was found necessary when using
palladium as chemical modifier with citric acid as a reduc-
ing agent. It ensures the presence of reduced palladium at
the very early stages of the temperature program [33,34].
It was also reported that the introduction of a pre-pyroly-
sis step in the temperature program helps the removal of
smoke, especially when analysing matrices rich in organic
matter [30]. In an attempt to optimize the temperature
program for beryllium determination in serum, we first
measured the relative absorbance of beryllium in a 5-fold
diluted non spiked serum at a fixed atomization tempera-
ture (2900°C) while varying the pyrolysis temperature
from 700 to 1400°C. We found that the optimal pyrolysis
temperature generating the highest beryllium signal was
1000°C. We then fixed the pyrolysis temperature at its
optimal temperature and varied the atomization temper-
atures between 2300 and 2900°C and found that the opti-
mal atomization temperature was 2900°C. The
background signal was decreased by 79% when pyrolysis
temperature was increased from 800 to 1000°C. The same
optimization work was reproduced for beryllium in an 8-
fold diluted non spiked blood. The optimal pyrolysis tem-
perature was found to be 800°C while the optimal atom-
ization temperature was found at 2800°C. Background
signal decreased by 48% when we ramped the pyrolysis
temperature from 800 to 900°C but the beryllium absorb-
ance also decreased by 10%. Figure 1 shows the complete
pyrolysis and atomization diagram of beryllium in serum
and blood.
Palladium/citric acid as a chemical modifier
Reduced palladium is an excellent modifier for GFAAS. It
decreases matrix interferences, prevents elements vapori-
zation during pyrolysis. It also generates a reproducible
signal at high atomization temperatures due to the forma-
tion of Pd-metal compound [35-37]. We used citric acid as
a reducing agent over ascorbic acid in order to eliminate
excess injection. Ascorbic acid needs to be prepared andChemistry Central Journal 2008, 2:14 http://journal.chemistrycentral.com/content/2/1/14
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injected separately because it instantly reduces the palla-
dium at room temperature while nitric acid only reduces
palladium at higher temperatures [33]. At their respective
optimal pyrolysis and atomization temperatures, 10 μL of
the working palladium/citric acid solutions was co-
injected with 20 μL of either 5-fold diluted serum or 8-
fold diluted blood. For beryllium in serum, no statistically
significant changes (one-sample T-test, p > 0.05) were
noticed in the relative absorbance when 3 or 6 μg of pal-
ladium were introduced in the graphite furnace (an
increase of 1.8 and 1.9% respectively). In contrast, the rel-
ative absorbance of beryllium continuously decreased
when higher amounts of palladium were tested reaching a
14% reduction at 20 μg (Figure 2). The background signal
increased dramatically by 130% when only 3 μg of palla-
dium was used and continued to increase with increasing
palladium mass introduced into the graphite furnace,
reaching a maximum of 150%. We also noticed a change
in the appearance of a background signal on top of the
beryllium signal (Figure 3) that kept increasing linearly
with the increasing mass of palladium injected in the
graphite tube (y = 0.0091 x ; r2 = 0.93). For beryllium in
blood, no statistically significant changes were observed
in the relative absorbance measured following the addi-
tion of 3 μg of palladium, yielding a 1.6% increase fol-
lowed by a continuous decrease as the quantity of
introduced palladium increased, up to an 8% reduction at
20 μg (Figure 2). The background signal of blood also
increased with increasing palladium quantities and had a
similar pattern of that found for beryllium in serum with
the appearance of a background signal on top on the
beryllium signal (Figure 3). The increase in the back-
ground signal varied from 133% at 3 μg, reaching a maxi-
mum of 165% for 20 μg of injected palladium (y = 0.0095
x ; r2  = 0.94). Since the obtained background signal
increased linearly with an increasing mass of injected pal-
ladium into the graphite tube, it is likely that this was due
the atomization of the reduced palladium itself (boiling
temperature of 2963°C). Because of the non-significant
improvements in the relative absorbance and the increase
in background signal, palladium/citric acid was not
retained as a chemical modifier for beryllium in blood or
serum.
Magnesium as chemical modifier
The same experimental set-up was used to study the effect
of magnesium on the relative absorbance of beryllium in
5-fold diluted serum and 8-fold diluted blood samples at
their optimal pyrolysis and atomization temperatures. In
serum, magnesium suppressed the relative absorbance of
Thermal pre-treatment pyrolysis and atomization curves for 5-fold diluted non spiked serum and 8-fold diluted non spiked  blood without the addition of any chemical modifiers Figure 1
Thermal pre-treatment pyrolysis and atomization curves for 5-fold diluted non spiked serum and 8-fold diluted non spiked 
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beryllium. This suppression increased with the increasing
mass of magnesium introduced into the graphite furnace
and varied from 2.5% at 3 μg to 23% at 20 μg (Figure 4).
The background signal increased significantly by 50%
when only 3 μg of Mg was introduced in the graphite fur-
nace reaching a maximum of 80% when 20 μg of Mg was
used as chemical modifier. We also noticed a change in
the pattern of the background signal. A second back-
ground peak was noticed at around 2000°C (Figure 3),
which increased linearly in intensity with increasing mass
of magnesium injected into the graphite tube (y = 0.0071
x ; r2 = 0.93). Such an observation confirms that the sec-
ond background peak was caused by the atomization of
magnesium. As for beryllium in blood, we found that the
addition of magnesium nitrate as a chemical modifier
tended to increase the relative absorbance of beryllium.
Influence of palladium mass on the relative absorbance of beryllium in 8-fold diluted blood and 5-fold diluted serum samples Figure 2
Influence of palladium mass on the relative absorbance of beryllium in 8-fold diluted blood and 5-fold diluted serum samples.
Variations in the background signal; (a) blood without modifier; (b) blood with 15 μg of Palladium; (c) blood with 10 μg Magne- sium; (d) serum without modifier; (e) serum with 10 μg Palladium; (f) serum with 12 μg Magnesium Figure 3
Variations in the background signal; (a) blood without modifier; (b) blood with 15 μg of Palladium; (c) blood with 10 μg Magne-
sium; (d) serum without modifier; (e) serum with 10 μg Palladium; (f) serum with 12 μg Magnesium.Chemistry Central Journal 2008, 2:14 http://journal.chemistrycentral.com/content/2/1/14
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This increase is significant (T-test, p < 0.05) and reached a
maximum of 12% when 6 or 9 μg of magnesium were co-
injected with the blood sample into the graphite furnace.
The introduction of 3 μg also increased the relative inten-
sity of beryllium by 6%. At higher magnesium concentra-
tions, the relative absorbance of beryllium tended to
decrease (Figure 4). The background pattern was similar
to that found with serum, with the appearance of a second
background peak at ~2000°C (Figure 3). The background
intensity increased form 55% to 81% when we increased
the concentration of introduced magnesium from 3 μg to
20 μg (y = 0.0074 x ; r2 = 0.95). 6-μg amount of magne-
sium was retained as a chemical modifier for beryllium in
blood despite the increase in the background signal
because it appears earlier in the temperature program and
does not interfere with the beryllium signal (Figure 3).
Analysis of blood
Analysing undigested blood by GFAAS could be problem-
atic due to the build-up of carbon residues in the graphite
tube. Therefore, an 8-fold dilution of blood with the Nash
reagent coupled with an optimal temperature program
eliminated the deposition of carbon. Neither the preci-
sion nor the sensitivity was affected after at least 100 injec-
tions, as verified by the analysis of the reconstituted blood
control material (STEWB level 2). We also performed a
standard addition on the reconstituted blood control to
validate the use of aqueous calibration and found no sig-
nificant differences between both curves (y = 0.0692 x -
0.0019 ; r2 = 0.99 for the aqueous calibration and y =
0.0682 - 0.0022; r2 = 0.99 for the standard addition on the
reconstituted blood control). Using the optimal tempera-
ture program for the 8-fold diluted blood and an aqueous
beryllium standard with 6 μg of magnesium nitrate as
chemical modifier, we measured the beryllium concentra-
tion in the blood of ten non-exposed individuals and
found that it varied from 0.48 to 0.74 μg L-1 with an aver-
age of 0.63 ± 0.08 μg L-1 (± SD) (Table 1). We obtained a
slightly lower mean beryllium concentration in blood
than reported by [22], (0.94 ± 0.38 μg L-1 (n = 10)). No
significant differences were found between the two sets of
data due to the large standard deviation reported in the
previous study. Beryllium concentrations in blood of non-
occupationally exposed individuals depend on a variety of
factors such as smoking, eating and drinking habits, as
those represent the main exposure routes for beryllium
intake [38].
The method detection limit was determined as the con-
centration corresponding to three times the standard devi-
ation of 8 replicates of the lowest standard (0.05 μg L-1).
We found a beryllium detection limit of 7 ng L-1 in blood.
Influence of magnesium mass on the relative absorbance of beryllium in 8-fold diluted blood and 5-fold diluted serum samples Figure 4
Influence of magnesium mass on the relative absorbance of beryllium in 8-fold diluted blood and 5-fold diluted serum samples.Chemistry Central Journal 2008, 2:14 http://journal.chemistrycentral.com/content/2/1/14
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The beryllium characteristic mass was found to be 0.20 (±
0.02) pg, of the same order of magnitude as that reported
by the manufacturer: 0.5 pg determined in 0.1% nitric
acid matrix. It was calculated as the mass of beryllium in
8-fold diluted blood that yields an absorbance equal to
0.0044 (1% absorption) in the peak height mode, with a
new pyrolytic coated graphite tube and under the optimal
furnace temperature program [39]. This similarity in the
beryllium characteristic mass reassures us that our experi-
mental conditions have eliminated signal suppression for
the blood matrix. The accuracy of the method was verified
by analysing the STEWB level 2 control sample with a
beryllium concentration of 5.9 (± 0.5) μg L-1. Accuracy
values of four different control samples prepared by 10 or
20-fold dilution of STEWB level 2 with NR were found to
be 100 (± 1) %. For the actual 10 samples we tested, nei-
ther sex nor smoking habit had a statistically significant
influence on the concentration of beryllium in blood (T-
test, p > 0.05), but for the two smokers, data points were
higher. A larger dataset would be necessary to properly
explore exposure questions and may yield interesting dif-
ferences.
Analysis of serum
We found that beryllium concentrations in the serum of
ten non-exposed individuals, analysed under optimal
temperature, using aqueous beryllium standards without
any chemical modification, varied from 0.40 to 0.49 μg L-
1 with an average of 0.43 ± 0.03 μg L-1 (± SD) (Table 1).
The beryllium detection limit was found to be 2 ng L-1
determined as the concentration corresponding to three
times the standard deviation of 12 replicates of the lowest
calibration standard (0.05 μg L-1). The beryllium charac-
teristic mass in 5-fold diluted serum was found to be 0.22
(± 0.07) pg, slightly lower than that reported by the man-
ufacturer: 0.5 pg determined in 0.1% nitric acid matrix
[39]. This also confirms that no signal suppression was
caused by the serum matrix under our experimental con-
ditions. The accuracy of the method was verified using the
same control material (STEWB level 2). We obtained an
accuracy of 97.5 (± 2.5)% on four different control sam-
ples. As observed earlier for blood, no significant influ-
ence of beryllium concentration in serum is attributed to
sex or smoking (T-test, p > 0.05).
Conclusion
We found a significant difference between the beryllium
concentration in blood and serum (p < 0.05). We meas-
ured higher beryllium concentration in blood than in
serum. On average, we noted a 30 ± 10% increase in the
blood beryllium concentration over serum. These find-
ings suggest that roughly two thirds of the beryllium con-
centration in the blood stream is found in the serum and
only one third is attached to the blood clot. Despite the
complexity of serum and blood matrices, no signal sup-
pression was noticed following our optimal conditions
and our beryllium detection limits (2 to 7 ng L-1) using the
Varian AA280Z Zeeman atomic absorption spectrometer
are among the lowest reported to date. [40] and [26],
reported a detection limit of 370 ng L-1 and 4.3 ng L-1
respectively for beryllium in urine by graphite furnace
atomic absorption spectrometry. In a similar work, [27],
and [24], reported a detection limit of 50 ng L-1 for beryl-
lium in urine. In water, [25] found 2.3 ng L-1 while [41],
found 10 ng L-1. The proposed method is ideally suited to
evaluate occupational exposure and other factors contrib-
uting to beryllium risks.
Experimental
Instrumentation
A Varian AA280Z Zeeman atomic absorption spectrome-
ter, equipped with a Zeeman background corrector, a GTA
120 graphite tube atomizer and a PSD 120 programmable
sample dispenser was used for the atomic absorption
measurement of beryllium at 234.9 nm with a spectral
band width of 1.0 nm. A beryllium hollow cathode lamp
(Varian, Part No. 5610100500) was used as a light source
operated at 5 mA. Pyrolytic graphite-coated partitioned
tubes (Varian partition tubes, Part No. 63-100012-00)
were used in all experiments. High purity argon (99.99%)
was used as the carrier gas. Instrument control, sample
results, signal graphics and data collection are controlled
by the SpectrAA Worksheet software for Windows® XP
operating system (Version 5.1, Varian, Australia 1997–
2006). Peak areas were used for the optimisation of the
furnace program, the choice of the appropriate experi-
mental setup and the quantification of beryllium in blood
and serum. The furnace programs for serum and blood
analysis are listed in Table 2.
Table 1: Beryllium contents in blood and serum of ten 
individuals. Averages of triplicate measurements with standard 
deviations are given.
Sample Sex Smoker Blood (μg L-1)S e r u m  ( μg L-1)
1F † S 0.71 ± 0.09 0.49 ± 0.08
2 F NS 0.64 ± 0.09 0.43 ± 0.09
3 F S 0.74 ± 0.06 0.45 ± 0.08
4 F NS 0.67 ± 0.08 0.40 ± 0.08
5 F NS 0.57 ± 0.06 0.46 ± 0.09
6 M NS 0.68 ± 0.04 0.40 ± 0.05
7 F NS 0.64 ± 0.08 0.41 ± 0.04
8 F NS 0.67 ± 0.09 0.42 ± 0.04
9 F NS 0.48 ± 0.06 0.43 ± 0.03
10 M‡ NS 0.55 ± 0.07 0.42 ± 0.06
Mean 0.63 ± 0.08 0.43 ± 0.03
† Female; ‡ Male;  Smoker;  non smoker.Chemistry Central Journal 2008, 2:14 http://journal.chemistrycentral.com/content/2/1/14
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Reagents and solutions
All reagents are of analytical grade, unless otherwise
stated. Antifoam B silicone emulsion (J.T. Baker, NJ,
USA), ammonium hydroxide (certified A.C.S. Plus, Fisher
scientific, NJ, USA), beryllium standard solution
(Specpure, Alfa Aesar, MA, USA), palladium matrix mod-
ifier (Sigma-Aldrich, USA), ethylenediaminetetraacetic
acid disodium salt dihydrate (EDTA) (Fluka Chemika,
Switzerland), nitric acid (trace metal grade, Fisher Scien-
tific, Ontario, Canada), Triton X-100 (Acros, NJ, USA), cit-
ric acid and magnesium nitrate were purchased from
Fisher-scientific (Ottawa, Ont, Canada). Seronorm trace
elements whole blood (STEWB) Level 2 (Ref # 201605;
Lot # 0503109) was purchased from SERO (Billingstad,
Norway).
Blood and serum samples were diluted with a Nash Rea-
gent (NR) prepared weekly containing 5% (v/v) nitric
acid, 5% (v/v) of ammonium hydroxide, 0.2% (v/v) Tri-
ton X-100, 0.2% (v/v) antifoam B and 0.5% (w/v) of
EDTA. A 50 μg L-1 working beryllium(II) solution was pre-
pared by dilution of the beryllium stock solution (1000
μg L-1) in 2% (v/v) HNO3. Beryllium standard solution
was prepared daily by dilution of the working beryl-
lium(II) solution with the Nash Reagent to give a final
concentration of 0.5 μg L-1. A series of palladium working
solutions containing 300, 600, 1000, 1200, 1500 and
2000 mg L-1 were prepared by dilution of the stock solu-
tion (10 000 mg L-1) in 2% (v/v) HNO3 and 2% (w/v) cit-
ric acid aqueous solutions. Another series containing 300,
600, 1000, 1200, 1500 and 2000 mg L-1  magnesium
nitrate was prepared by dissolving the appropriate mass in
2% (v/v) HNO3 aqueous solution. A 10-μL volume of the
chemical modifier or Nash Reagent (when no modifier is
used) was co-injected with 20-μL of the sample into the
furnace.
Blood and serum Samples
Blood and serum samples of 10 individuals (8 females
and 2 males) were collected respectively in BD Vacutaine
(sodium Heparin) and BD Vacutaine (SST) respectively
(BD Franklin lakes (NJ, USA)). All subjects live in the
region of Montreal, Quebec, Canada with no previous his-
tory of occupational exposure to beryllium, from ques-
tionnaire-based interviews. Blood was diluted 8-fold and
serum 5-fold with the Nash Reagent. Triplicates of blood
and serum samples were refrigerated at 4°C until analysis.
All samples were analysed on the day of collection.
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